羟氯喹用于斯里兰卡海军人员COVID-19暴露后预防:随机对照试验研究方案
本研究为安慰剂对照随机临床试验,在斯里兰卡海军基地和检疫中心开展,对象为暴露于COVID-19确诊患者但rRT-PCR阴性的海军人员,随机分配每臂200人接受羟氯喹或安慰剂,随访14天观察症状或SARS-CoV-2 rRT-PCR阳性。旨在评估羟氯喹用于COVID-19暴露后预防的有效性和安全性。
要点
- 每臂200人随机接受羟氯喹或安慰剂,随访14天观察转阳或症状。
- 研究对象为暴露于COVID-19患者但rRT-PCR阴性的海军人员。
- 试验在严格非药物公共卫生措施背景下评估羟氯喹暴露后预防。
核心结论
- 本试验旨在提供羟氯喹作为COVID-19暴露后预防的有效性和安全性高质量证据。
研究设计与样本
- 安慰剂对照、随机临床试验,在斯里兰卡海军基地营地和检疫中心开展。
- 暴露于COVID-19确诊患者但rRT-PCR阴性的海军人员随机分配,每臂200人接受羟氯喹或安慰剂。
- 随访14天监测症状出现或SARS-CoV-2 rRT-PCR阳性。
关键数值与推荐
- 每臂随机分配200人接受羟氯喹或安慰剂。
- 随访14天观察症状或rRT-PCR阳性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The first case of a coronavirus 2019 (COVID-19) infection in a Sri Lankan was reported on March 11, 2020. The situation in Sri Lanka changed with the rapid increase of personnel contracting COVID-19 in a naval base camp that housed more than 4000 people. This provided a unique opportunity to study the effectiveness of hydroxychloroquine (HCQ) for post-exposure prophylaxis (PEP), while taking stringent, non-pharmacologic, public health measures to prevent spread. Our aim is to study the effectiveness and safety of HCQ for PEP among naval personnel with exposure to COVID-19-positive patients. METHODS/DESIGN: This is a placebo-controlled, randomized, clinical trial carried out in the naval base camp and quarantine centers of the Sri Lanka Navy, Ministry of Defense, Sri Lanka. Navy personnel who are exposed to a patient with confirmed COVID-19 infection but test negative for the virus on reverse real-time polymerase chain reaction (rRT-PCR) at recruitment will be randomized, 200 to each arm, to receive HCQ or placebo and monitored for the development of symptoms or rRT-PCR positivity for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus for 14 days. DISCUSSION: This trial will provide high-quality evidence of the effectiveness and safety of HCQ as PEP for COVID-19. The study design is unique due to the circumstances of the outbreak in a confined area among otherwise healthy adults, at a relatively early stage of its spread. TRIAL REGISTRATION: Sri Lanka Clinical Trials Registry (SLCTR) SLCTR/2020/011 . Registered on 04 May 2020.
引用
- Niriella MA, Ediriweera DS, De Silva AP, et al. Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial. Trials. 2020. PMID: 32854751. doi:10.1186/s13063-020-04659-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。